TNF and rheumatoid arthritis: A recent post hoc analysis of the subpopulations in the ORAL Surveillance, an event-driven clinical trial of risk-enriched patients with rheumatoid arthritis, identified subpopulations with a different relative risk of predefined adverse events with tofacitinib vs tumor necrosis factor inhibitors (TNFis) (36).